Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-SERP "25" vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Hypertension
Hypertension
Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Reserpine: terminal elimination half-life 33-45 hours (range 30-60 hours), with clinical context of prolonged autonomic effects lasting days; hydrochlorothiazide: terminal half-life 6-15 hours (mean 10 hours).
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Hydrochlorothiazide is not extensively metabolized; reserpine is extensively metabolized in the liver via CYP450 enzymes.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal (approximately 30-50% as unchanged drug and metabolites), biliary/fecal (approximately 50-70% as metabolites, with enterohepatic recirculation noted for reserpine component).
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Reserpine: 95-98% bound to plasma proteins; hydrochlorothiazide: 60-70% bound to albumin.
Approximately 70-80% bound to plasma proteins, primarily albumin.
Reserpine: Vd approximately 0.5-0.7 L/kg, indicating extensive tissue distribution and high lipophilicity; hydrochlorothiazide: Vd 0.2-0.4 L/kg, primarily confined to extracellular fluid.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Reserpine: oral bioavailability approximately 50% due to first-pass metabolism; hydrochlorothiazide: oral bioavailability 65-75%.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
GFR 30-50 m L/min: 25 mg once daily. GFR 15-29 m L/min: not recommended. GFR <15 m L/min: contraindicated.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh Class A or B: no adjustment. Child-Pugh Class C: use with caution, consider starting at 12.5 mg daily.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Weight-based: 1-2 mg/kg/day orally divided every 12-24 hours, maximum 100 mg/day.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Start at 12.5 mg daily; monitor electrolytes and renal function; may increase to 25 mg daily if needed.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None
None.
May cause electrolyte imbalance (hypokalemia, hyponatremia),May exacerbate systemic lupus erythematosus,Reserpine may cause mental depression, peptic ulcer, and nasal congestion,Photosensitivity,Orthostatic hypotension with reserpine
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Anuria,Sulfonamide allergy (hydrochlorothiazide is a sulfonamide),Known hypersensitivity to hydrochlorothiazide or reserpine,Active peptic ulcer (due to reserpine),Electroconvulsive therapy (within 7 days, due to reserpine)
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid high-sodium foods to enhance antihypertensive effect. Limit alcohol intake as it may potentiate hypotension. Grapefruit juice may alter drug metabolism; avoid excessive consumption. Maintain adequate potassium intake (bananas, oranges) unless advised otherwise by your doctor.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
FDA Pregnancy Category D. Use of reserpine in the first trimester is associated with an increased risk of congenital malformations, including neural tube defects and cardiovascular anomalies. In the second and third trimesters, exposure may cause fetal bradycardia, hypothermia, and respiratory depression due to depletion of catecholamines. Chronic use may lead to fetal growth restriction.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Reserpine is excreted into breast milk with an M/P ratio of 0.5. Due to the potential for serious adverse reactions in nursing infants, including gastrointestinal disturbances, nasal congestion, and lethargy, breastfeeding is contraindicated during reserpine therapy.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No pharmacokinetic studies are available to guide dosing adjustments during pregnancy; however, due to increased plasma volume and renal clearance, the effective dose may need to be increased, but this must be balanced against fetal risks. The lowest effective dose should be used and the drug should be discontinued if possible, especially during the third trimester to avoid neonatal effects.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Hydro-Serp '25' contains hydrochlorothiazide 25 mg and reserpine 0.125 mg. Monitor serum potassium and magnesium; hypokalemia increases digitalis toxicity risk. Reserpine may cause mental depression; use with caution in patients with history of depression. Taper reserpine before surgery to avoid hypertensive rebound. Avoid concurrent use with MAOIs.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take exactly as prescribed; do not discontinue abruptly.,This medication may make you dizzy or drowsy; avoid driving until you know how it affects you.,Rise slowly from sitting or lying to prevent falls from low blood pressure.,Report any mood changes, depression, or vivid dreams to your doctor.,Use sunscreen and protective clothing; this drug increases sun sensitivity.,Do not use potassium supplements or salt substitutes without asking your doctor.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-SERP "25" vs ALDOCLOR-150, answered by our medical review team.
HYDRO-SERP "25" is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-SERP "25" and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-SERP "25" is: Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-SERP "25" and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-SERP "25" is classified as Category C. FDA Pregnancy Category D. Use of reserpine in the first trimester is associated with an increased risk of congenital malformations, including neural tube defects and cardiovascular. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.